Results 51 to 60 of about 23,927 (264)

Thrombospondin in essential thrombocythemia [PDF]

open access: yesBlood, 1986
Abstract Essential thrombocythemia is a myeloproliferative disorder characterized by frequent bleeding and thrombotic complications. On a molecular level, two abnormalities of platelet thrombospondin have been identified: abnormal glycosylation of the intact 185,000-dalton chain has been detected and a shortened form of the ...
J, Lawler   +3 more
openaire   +3 more sources

Multinational transfusion practices and outcomes in haematology patients admitted to the intensive care unit

open access: yesVox Sanguinis, EarlyView.
Abstract Background and Objectives The number of critically ill patients with haematological conditions is increasing, yet transfusion practices in this population remain poorly defined. This study aimed to compare transfusion strategies in critically ill patients with versus without haematological conditions.
Caroline M. Schaap   +288 more
wiley   +1 more source

Essential thrombocythemia and acute myocardial infarction treated with rescue coronary angioplasty

open access: yesArquivos Brasileiros de Cardiologia, 1999
A 48-year-old man with essential thrombocythemia suffered an extensive anterior acute myocardial infarction; this is a rare association. A pharmacological thrombolysis was performed, without success.
Antonio Esteves Fº   +4 more
doaj   +1 more source

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2020
Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to determine the thrombotic event, including the interaction between platelets, leukocytes and ...
Vincenzo Accurso   +11 more
doaj   +1 more source

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]

open access: yes, 2019
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Annunziata, M.   +14 more
core   +1 more source

Sabotaged Integral HSC Heterogeneity Underlies Essential Thrombocythemia Development

open access: yesAdvanced Science, Volume 13, Issue 7, 3 February 2026.
Single‐cell RNA sequencing (scRNA‐seq) maps how distinct driver mutations remodel hematopoietic stem cell (HSC) programs across essential thrombocythemia (ET). Comparative analysis uncovers both shared and subtype‐specific molecular signatures, identifies a triple‐negative (TN)‐associated HSC population enriched with malignant traits, and reveals the ...
Jingyuan Tong   +21 more
wiley   +1 more source

Pretreatment with Hydroxyurea of the Patient with Essential Thrombocythemia Followed by Coronary Artery Bypass Surgery

open access: yesOman Medical Journal, 2014
The risk of thrombosis is high in patients with essential thrombocythemia. Special precaution needed for those patients who will undergo Coronary artery bypass grafting. We are reporting a 62 years old patient with ischemic heart disease who was found to
Edem Ziadinov   +3 more
doaj   +1 more source

Pathophysiological aspects of Platelet-Mediated Thrombosis and Bleeding in Essential Thrombocythemia: [PDF]

open access: yes, 1998
Thrombocytosis, i.e. an elevation of the platelet count, is a common finding in clinical practice. In general, patients with thrombocytosis are distinguished into two main categories, primarily based on the cause underlying the increased platelet count ...
Genderen, P.J.J. (Perry) van
core   +1 more source

Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias

open access: yesAdvanced Science, Volume 13, Issue 7, 3 February 2026.
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei   +32 more
wiley   +1 more source

Cavernous transformation of the portal vein associated with occult essential thrombocythemia [PDF]

open access: diamond, 2021
Miguel Ángel Montiel Alfonso   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy